Head and Neck Cancer Registry (LORHAN)
Completed
- Conditions
- Head and Neck Cancer
- Interventions
- Other: Therapy for head and neck cancer
- Registration Number
- NCT01080313
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26000
Inclusion Criteria
- Pathologically (histologically or cytologically) confirmed new diagnosis of carcinoma involving the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or neck node metastasis from unknown origin
- Scheduled to receive radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
- Written informed consent
Read More
Exclusion Criteria
- Registry participation does not exclude participation in clinical trials.
- Patients scheduled to receive or who have received surgery are eligible for Registry participation as long as they are also scheduled to receive medical therapy.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with head and neck cancer Therapy for head and neck cancer -
- Primary Outcome Measures
Name Time Method Patterns of care for head and neck cancer up to 10 years
- Secondary Outcome Measures
Name Time Method Overall survival by treatment regimen study entry to death from any cause or to end of study Determine the incidence and severity of major dose-limiting and other important treatment toxicities up to 10 years Identify supportive care received for managing nutrition, pain, nausea and other complications up to 10 years tumor control by treatment regimen study entry to progressive disease
Trial Locations
- Locations (1)
Mednet Solutions
🇺🇸Minnetonka, Minnesota, United States